Compare M&T Bank Corporation (MTB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs TransMedics Group Inc — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.37B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: M&T Bank Corporation is far larger — about 11.5× TransMedics Group Inc's market cap, and M&T Bank Corporation pays a 2.52% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MTB | TMDX | |
|---|---|---|
Market Cap | $34.37B | $3.00B |
Sector | Financials | Technology |
52-Week High | $254.09 | $150.42 |
52-Week Low | $178.63 | $61.99 |
Dividend Yield | 2.52% | — |
Enterprise Value | — | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.35 surpassing the $4.66 forecast. Revenue growth is steady, reaching $9.63 billion in 2025, and the net income margin is strong at 30.85%. A quarterly dividend of $1.50 per share was recently declared, payable in September 2026.
The outlook is positive, supported by earnings beats and a consensus price target of $261.62, implying nearly 10% upside. Key risks include a negative net cash flow of -$2.01 billion in 2025 and rising debt levels, while analyst sentiment is mixed with a 'Hold' consensus amid macroeconomic uncertainty.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
